British multinational pharmaceutical and biotechnology company GlaxoSmithKline (GSK) has announced the opening of a new SGD 44 million (USD 33 million) high potency facility (HPF) in its strategic New Product Introduction site in Jurong, Singapore. The HPF will be used to produce a key ingredient, which is a cytotoxic component, in antibody drug conjugates (ADCs) to treat cancer.
This facility is the first in Singapore capable of producing highly potent cytotoxic ingredients in ADCs, for breakthrough immunotherapy cancer treatments. It is equipped with advanced features such as specialized equipment, automated operations, containment capabilities and cross-contamination control. It is built to facilitate complete in-house manufacturing to safeguard supply chain processes, quality control and timeliness of delivery. It also features leading-edge capabilities to handle high-potency manufacturing in a safe and controlled environment.
With the addition of the HPF, GSK has further strengthened the Jurong site’s capabilities as a New Product Introduction (NPI) site to launch new products more quickly. The capability to produce high-potency components at scale helps to meet the increasing demand for oncology treatments worldwide.